Orion Pharma Limited announcements
187 Dhaka Stock Exchange announcements for Orion Pharma Limited (ORIONPHARM) since 2013: results, dividends, board meetings, AGMs, record dates and other price-sensitive information. Showing 2018 (14).
- Resumption after record date
Trading of the shares of the Company will resume on 25.11.2018 after record date.
- Suspension for Record date
Trading of the shares of the Company will remain suspended on record date i.e., 22.11.2018.
- Spot News
Trading of the shares of the Company will be allowed only in the Spot Market and Block transactions will also be settled as per Spot settlement cycle with cum benefit from 19.11.2018 to 20.11.2018. Trading of the shares of the Company will remain suspended on record date i.e., 22.11.2018.
- Q1 Financials
(Q1 Un-audited): Consolidated EPS was Tk. 0.98 for July-September, 2018 as against Tk. 1.10 for July-September, 2017; Consolidated NOCFPS was Tk. 2.62 for July-September, 2018 as against Tk. 2.53 for July-September, 2017. Consolidated NAV per share (including revaluation surplus) was Tk. 73.65 as on September 30, 2018 and Tk. 72.05 as on September 30, 2017. Consolidated NAV per share (excluding revaluation surplus) was Tk. 65.35 as on September 30, 2018 and Tk. 63.62 as on September 30, 2017.
- Board Meeting schedule under LR 16(1)
As per Regulation 16(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on November 14, 2018 at 5:00 PM to consider, among others, un-audited financial statements of the Company for the First Quarter (Q1) period ended on September 30, 2018.
- Dividend Declaration
The Board of Directors has recommended 15% cash dividend for the year ended on June 30, 2018. Date of AGM: 10.12.2018, Time: 11:00 AM, Venue: Officer's Club, 26, Baily Road, Ramna, Dhaka. Record Date: 22.11.2018. The Company has also reported Consolidated EPS of Tk. 3.43, Consolidated NAV per share (including Revaluation Surplus) of Tk. 72.88 and Consolidated NOCFPS of Tk. 9.38 for the year ended on June 30, 2018 as against Tk. 3.40, Tk. 70.95 and Tk. 9.62 respectively for the year ended on June 30, 2017.
- Price Limit Open
There will be no price limit on the trading of the shares of the Company today (01.11.2018) following its corporate declaration.
- Board Meeting schedule under LR 19(1)
As per Regulation 19(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on October 31, 2018 at 5:00 PM to consider, among others, audited financial statements of the Company for the year ended on June 30, 2018.
- Credit Rating Result
Credit Rating Agency of Bangladesh Limited (CRAB) has announced the Entity rating (Surveillance) of the Company as "A1" along with a stable outlook based on un-audited financial statements as of March 31, 2018, audited financial statement of the Company up to June 30, 2017; bank liability position as of April 30, 2018 and other relevant quantitative as well as qualitative information up to the date of rating declaration.
- Q3 Financials
(Q3 Un-audited): Consolidated EPS was Tk. 0.69 for January-March 2018 as against Tk. 0.56 for Jan.-Mar. 2017; Consolidated EPS was Tk. 2.76 for July'17-March'18 as against Tk. 3.02 for July'16-March'17. Consolidated NOCFPS was Tk. 8.57 for July'17-March'18 as against Tk. 8.54 for July'16-March'17. Consolidated NAV per share (including and excluding Revaluation Surplus) was Tk. 72.07 and Tk. 63.71 respectively as on March 31, 2018 as against Tk. 70.95 and Tk. 62.48 respectively as on June 30, 2017.
- Board Meeting schedule under LR 16(1)
As per Regulation 16(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on April 28, 2018 at 5:30 PM to consider, among others, un-audited financial statements of the Company for the Third Quarter (Q3) period ended on March 31, 2018.
- Q2 Financials
(Q2 Un-audited): Consolidated EPS was Tk. 0.97 for October-December, 2017 as against Tk. 1.29 for October-December, 2016; Consolidated EPS was Tk. 2.07 for July-December, 2017 as against Tk. 2.46 for July-December, 2016. Consolidated NOCFPS was Tk. 4.81 for July-December, 2017 as against Tk. 3.22 for July-December, 2016. (cont.) (Continuation news of ORIONPHARM): Consolidated NAV per share Including revaluation surplus was Tk. 71.46 as on December 31, 2017 and Tk. 70.95 as on June 30, 2017. Consolidated NAV per share Excluding revaluation surplus was Tk. 63.06 as on December 31, 2017 and Tk. 62.48 as on June 30, 2017. (end)
- Board Meeting schedule under LR 16(1)
As per Regulation 16(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on January 28, 2018 at 4:30 PM to consider, among others, un-audited financial statements of the Company for the Second Quarter (Q2) period ended on December 31, 2017.
- Dividend Disbursement
The Company has informed that it has disbursed cash dividend for the year ended on June 30, 2017.
Source: Dhaka Stock Exchange announcements. Some posts before 2014 have no title, and 2014–2020 coverage is incomplete.